Vera Therapeutics Files Q1 2025 10-Q
Ticker: VERA · Form: 10-Q · Filed: May 7, 2025 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech, R&D
TL;DR
Vera Therapeutics Q1 2025 10-Q filed. Cash, R&D expenses, and stock plans detailed.
AI Summary
Vera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position, including cash and equivalents, and detailed research and development expenses for the first quarter of 2025. The filing also covers equity incentive plans and stock-based compensation details.
Why It Matters
This filing provides investors with an update on Vera Therapeutics' financial health and operational expenses for the first quarter of 2025, crucial for assessing the company's progress and future outlook.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Vera Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 to 2025-03-31 — Q1 2025 R&D Expense Period (Covers the period for which Research and Development Expenses are reported.)
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250507 (date) — Filing date
- 2000 SIERRA POINT PARKWAY, SUITE 1200 (address) — Company business and mailing address
- BRISBANE, CA 94005 (address) — Company business and mailing city, state, zip
- 650-770-0077 (phone_number) — Company business phone
FAQ
What is the primary business of Vera Therapeutics, Inc.?
Vera Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What is the fiscal year end for Vera Therapeutics?
The fiscal year end for Vera Therapeutics is December 31.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 7, 2025.
What equity incentive plans are mentioned in the filing?
The filing mentions the Two Thousand And Seventeen And Two Thousand And Twenty-One Amended Equity Incentive Plan and the Two Thousand And Seventeen EIP Two Thousand And Twenty-One EIP And Two Thousand And Twenty-Four Inducement Plan.
What is the company's business address?
The company's business address is 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA 94005.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Vera Therapeutics, Inc. (VERA).